About this item:

55 Views | 33 Downloads

Author Notes:

Correspondence: Dimy Fluyau dfluyau@gmail.com

DF and PM separately conducted the literature search, extracted, and analyzed the data; separately scored the quality of the trials included in the review; summarized the results; wrote the manuscript.

DF developed the tables and figures.

KL played the role of moderator, proofread the manuscript, proposed word choice, and grammatically corrected sentences. KL also contributed to gathering and formatting the list of references.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Subjects:

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Psychiatry
  • amphetamine psychosis
  • psychosis
  • addictive disorders
  • treatment outcome
  • risk
  • amphetamine
  • antipsychotics
  • METHAMPHETAMINE-INDUCED PSYCHOSIS
  • RANDOMIZED CONTROLLED-TRIAL
  • CLINICAL-FEATURES
  • RISK-FACTORS
  • ARIPIPRAZOLE
  • DOPAMINE
  • SCHIZOPHRENIA
  • HALOPERIDOL
  • RISPERIDONE
  • DEPENDENCE

Antipsychotics for Amphetamine Psychosis. A Systematic Review

Tools:

Journal Title:

Frontiers in Psychiatry

Volume:

Volume 10

Publisher:

, Pages 740-740

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: Among individuals experiencing amphetamine psychosis, it may be difficult to rule out schizophrenia. The use of antipsychotics for the treatment of amphetamine psychosis is sparse due to possible side effects. Some arguments disfavor their use, stating that the psychotic episode is self-limited. Without treatment, some individuals may not fully recover from the psychosis and may develop full-blown psychosis, emotional, and cognitive disturbance. This review aims to investigate the clinical benefits and risks of antipsychotics for the treatment of amphetamine psychosis. Methods: Electronic search on trials on antipsychotic drugs for amphetamine psychosis from their inception to November 2018 was conducted in PubMed, Scopus, Google Scholar, EBSCOhost, ProQuest, Cochrane Review Database, Medline Ovid, and EMBASE following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The Cochrane risk-of-bias tool assessed the risk of bias, the methodological quality of individual trials was assessed by the Oxford Quality Scoring System, and the quality of evidence for recommendations was judged by the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). The results were synthesized qualitatively and quantitatively. Results: The investigation of six randomized controlled trials of 314 participants showed that aripiprazole, haloperidol, quetiapine, olanzapine, and risperidone were able to reduce or control the psychotic episode (positive and negative symptoms) induced by amphetamine use with no adverse event. Although the side-effect profile of these agents varied, no drug was clinically superior to others. Conclusions: This review suggests that antipsychotics seem to be efficacious for amphetamine psychosis on both positive and negative symptoms. Practitioners need to tailor their use based on risks for side effects individually.

Copyright information:

© Copyright © 2019 Fluyau, Mitra and Lorthe.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote